IP Library Granted Patent US 7,955,605
Granted Patent B2
US 7,955,605 · App. 11/644,095 · Granted Jun 7, 2011

Multivalent pneumococcal polysaccharide-protein conjugate composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,955,605
App. No.
11/644,095
Granted
Jun 7, 2011
Kind
B2
Abstract

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.

Claims (35)

1. A method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide covalently linked to a carrier protein, the method comprising:

(a) reacting purified serotype 19A polysaccharide with an oxidizing agent resulting in an activated serotype 19A polysaccharide;

(b) compounding the activated serotype 19A polysaccharide with a carrier protein;

(c) co-lyophilizing the compounded activated serotype 19A polysaccharide and carrier protein;

(d) re-suspending the compounded activated serotype 19A polysaccharide and carrier protein in dimethyl sulfoxide (DMSO):

(e) reacting the compounded, activated serotype 19A polysaccharide and carrier protein with a reducing agent resulting in a serotype 19A polysaccharide:carrier protein conjugate; and

(f) capping unreacted aldehydes in the serotype 19A polysaccharide:carrier protein conjugate resulting in an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide covalently linked to a carrier protein; wherein step (c) is performed after step (b) and before steps (d) and (e).

2. The method of claim 1 , wherein the carrier protein is CRM197.

3. The method of claim 2 , wherein the activated serotype 19A polysaccharide and CRM197 are compounded at a ratio of 0.8:1.

4. The method of claim 1 , wherein the pH of the activated serotype 19A polysaccharide is adjusted to 6.5±0.2 prior to compounding with the carrier protein.

5. The method of claim 1 , wherein the activated serotype 19A poiysaccharide is compounded with sucrose prior to compounding with the carrier protein.

6. The method of claim 1 , further comprising purifying the immunogenic conjugate.

7. The method of claim 1 , wherein the oxidizing agent is sodium periodate.

8. The method of claim 1 , wherein the reducing agent is sodium cyanoborohydride,

9. The method of claim 1 , wherein capping unreacted aldehydes comprises reacting the serotype 19A polysaccharide:carrier protein conjugate with sodium borohydride.

10. A method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide covalently linked to a carrier protein, the method comprising:

(a) reacting purified serotype 19A polysaccharide with sodium periodate resulting in an activated serotype 19A polysaccharide;

(b) adjusting the pH of the activated serotype 19A polysaccharide to 6.5±0.2;

(c) compounding the activated serotype 19A polysaccharide with sucrose;

(d) compounding the activated serotype 19A polysaccharide with a carrier protein at a ratio of 0.8:1;

(e) co-lyophilizing the compounded activated serotype 19A polysaccharide and carrier protein;

(f) re-suspending the compounded activated serotype 19A polysaccharide and carrier protein in dimethyl sulfoxide (DMSO);

(g) reacting the compounded, activated serotype 19A polysaccharide and carrier protein with sodium cyanoborohydride resulting in a serotype 19A polysaccharide:carrier protein conjugate; and

(h) capping unreacted aldehydes in the serotype 19A polysaccharide:carrier protein conjugate with sodium horohydride resulting in an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide covalently linked to a carrier protein; wherein step (e) is performed after step (d) and before steps (f) and (g).

11. The method of claim 10 , wherein the carrier protein is CRM197.

12. The method of claim 10 , further comprising purifying the immunogenic conjugate,

13. A method for making an immunogenic conjugate comprising a Streptococcus pneumoniae polysaccharide covalently linked to a carrier protein wherein said polysaccharide comprises a phosphodiester linkage between repeat units, the method comprising:

(a) reacting said polysaccharide with an oxidizing agent resulting in an activated polysaccharide;

(b) compounding the activated polysaccharide with a carrier protein;

(c) co-lyophilizing the compounded activated polysaccharide and carrier protein;

(d) re-suspending the compounded activated polysaccharide and carrier protein in dimethyl sulfoxide (DMSO);

(e) reacting the compounded, activated polysaccharide and carrier protein with a reducing agent resulting in a polysaccharide:carrier protein conjugate; and

(f) capping unreacted aldehydes in the polysaccharide:carrier protein conjugate resulting in an immunogenic conjugate comprising Streptococcus pneumoniae polysaccharide covalently linked to a carrier protein; wherein step (c) is performed after step (b) and before steps (d) and (e).

14. The method of claim 13 , wherein said polysaccharide comprising a phosphodiester linkage between repeat units is Streptococcus pneumoniae polysaccharide serotype 19A, 19F, 6A, or 6B.

15. The method of claim 13 , wherein the carrier protein is CRM197.

Assignments (4)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 27, 2023
From: WYETH LLC
To: WYETH LLC
Reel/Frame 063165/0455 →
ASSIGNEE ADDRESS CORRECTION Recorded Sep 15, 2017
From: WYETH LLC
To: WYETH LLC
Reel/Frame 043969/0813 →
CHANGE OF NAME Recorded Jun 16, 2010
From: WYETH
To: WYETH LLC
Reel/Frame 024541/0922 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2007
From: HAUSDORFF, WILLIAM P.; SIBER, GEORGE RAINER; PARADISO, PETER R.; PRASAD, A. KRISHNA
To: WYETH
Reel/Frame 019616/0398 →